Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog

Category: biotech/medical

The remains reveal that Waal was between 35 and 50 years old when he died. Researchers used techniques including radiocarbon dating, stratigraphy and ceramic typology to determine that people buried him in around 726 A.D., the same year workers built the hieroglyphic staircase, notes Notimerica.

Prior to his death, Waal suffered from a variety of medical ailments. His skull was mildly flattened, and he was malnourished as a child, as evidenced by the “slightly porous, spongy areas known as porotic hyperostosis, caused by childhood nutritional deficiencies or illnesses” on the sides of his head, per the statement.

Scientists also found that infections, trauma, scurvy or rickets had triggered periostitis —chronic swelling and pain—to form in Waal’s arm bones.

Read more | >

Long but annotated! Most important here is human data for specific treatments due out starting in May or June. And apparently they had a mouse study where they expected a paper due out already but other groups chimed in to help with more testing so there is a delay.

Liz Parrish, CEO of BioViva Science and patient zero of biological rejuvenation with gene therapies, is interviewed by Zora Benhamou on her fresh podcast “HackMyAge”.

During the conversation, Liz enters deep into the world of gene therapies, either to cure monogenic diseases, multifactorial genetic diseases, or the mother of all diseases: aging itself.

The conversation lasts for one hour and twenty minutes and has no waste. However, to go direct to certain themes use the following time marks:

0:00:00 Zora introduces the podcast: who is Liz Parrish and what the conversation will be about.
0:02:17 Liz Parrish begins her intervention in the podcast.
0:03:00 What is gene therapy and how Liz got involved in gene therapy applied to aging.
0:05:52 How Liz and her son are dealing with the treatment of type 1 diabetes.
0:08:05 How Liz got involved in becoming the first human treated with gene therapy to treat biological aging and what it means to go through gene therapy.
0:14:34 Current legal status of gene therapies and ways to get the treatment.
0:16:20 Current costs of undergoing gene therapies.
0:18:49 Why aren’t medical doctors applying gene therapies more than they actually are and what’s the role of medical tourism.
0:21:34 What prompted Liz to become the first patient to undergo gene therapy for biological aging.
0:25:25 How gene therapies compare with nutraceuticals and pharmaceuticals.
0:30:05 Why big pharmaceutical companies haven’t jumped into the field with more impetus.
0:33:20 How long will it take for gene therapies to become mainstream.
0:39:29 How gene therapies work and what is the experience for the patient that goes through it.
0:48:11 What can be expected from treating sarcopenia with gene therapy.
0:50:02 Where do the genes used in gene therapies come from.
0:53:12 What can expect someone who is treated with gene therapy to tackle dementia.
0:54:34 What are the major changes experienced by Liz in her blood markers since being treated.
0:56:38 When and how did Liz go through her gene therapies, not only for hTERT and Follistatin but also for Klotho and PGC-1alpha. What are the latter two all about?
1:02:15 How Liz envision the future of humans.
1:04:08 Liz comments on a coming paper BioViva is working together with Rutgers University.
1:05:38 Other studies in the pipeline.
1:06:45 Explanation of testing services and data storage offered by BioViva.
1:17:20 Liz on topical creams and/or small molecules for removal of senescent cells, and pills for telomeres lengthening.
1:19:16 Liz responds to “if you could meet your 20-year-old self what would you tell her”
1:20:03 What can people do to help Liz on her mission.
1:22:12 Resources to learn more about the future that is coming, genomics and gene therapy technology.
1:24:18 BioViva and Integrated Health Systems websites as well as social media sites where Liz and BioViva are actively present.
1:25:38 Words of farewell.

Websites:
HackMyAge: https://hackmyage.com/
BioViva Science: https://bioviva-science.com/
Integrated Health Systems: https://www.integrated-health-systems.com/

Read more | >

Kent Taylor, the co-founder and CEO of Texas Roadhouse Inc., has died from suicide, his family said, after suffering “unbearable” COVID-19-related symptoms.

Taylor’s family and the restaurant chain said in a statement to The Hill on Sunday that the business executive “took his own life this week” after “a battle with post-Covid related symptoms, including severe tinnitus.”

“Kent battled and fought hard like the former track champion that he was, but the suffering that greatly intensified in recent days became unbearable,” the statement read.

Read more | >

Here’s my latest video!

In November 2020, I made a HDL video based on a meta-analysis in ~3.4 million subjects that was published in July 2020. In Dec 2020, a larger study (n=15.8 million subjects) was published-those data are presented in the video, and compared against the meta-analysis.

In addition, I’ve tested my HDL 2 more times since November 2020, so how’s my progress for getting it into the optimal range? Also, I attempt to derive clinical significance by identifying correlations for higher HDL with lower Lp(a) and hs-CRP.

Studies referenced in the video:
High-density lipoprotein cholesterol and all-cause mortality by sex and age: a prospective cohort study among 15.8 million adults:
https://pubmed.ncbi.nlm.nih.gov/33313654/

HDL-C is associated with mortality from all causes, cardiovascular disease and cancer in a J-shaped dose-response fashion: a pooled analysis of 37 prospective cohort studies:
https://pubmed.ncbi.nlm.nih.gov/32283957/

Use of Lipoprotein(a) in clinical practice: A biomarker whose time has come. A scientific statement from the National Lipid Association:
https://pubmed.ncbi.nlm.nih.gov/31147269/

CRP studies:
Beta2-microglobulin for risk stratification of total mortality in the elderly population: comparison with cystatin C and C-reactive protein:
https://pubmed.ncbi.nlm.nih.gov/31147269/

High-Sensitivity C-Reactive Protein and Risks of All-Cause and Cause-Specific Mortality in a Japanese Population:
https://pubmed.ncbi.nlm.nih.gov/27268644/

Read more | >

Summary: A new genetic engineering strategy significantly reduces levels of tau in animal models of Alzheimer’s disease. The treatment, which involves a single injection, appears to have long-last effects.

Source: Mass General.

Researchers have used a genetic engineering strategy to dramatically reduce levels of tau–a key protein that accumulates and becomes tangled in the brain during the development of Alzheimer’s disease–in an animal model of the condition.

Read more | >

The Research Group on Synthetic Biology for Biomedical Applications at Pompeu Fabra University in Barcelona, Spain, has designed a cellular device capable of computing by printing cells on paper. For the first time, they have developed a living device that could be used outside the laboratory without a specialist, and it could be produced on an industrial scale at low cost. The study is published in Nature Communications and was carried out by Sira Mogas-Díez, Eva Gonzalez-Flo and Javier Macía.

We currently have many available to us such as computers and tablets whose computing power is highly efficient. But, despite their power, they are very limited devices for detecting biological markers, such as those that indicate the presence of a disease. For this reason, a few years ago ‘biological computers’ began to be developed—in other words, living cellular devices that can detect multiple markers and generate complex responses. In them, the researchers leverage biological receptors that allow detecting exogenous signals and, by means of , modify them to emit a response in accordance with the information they detect.

So far, cellular devices have been developed that must operate in the laboratory, for a limited time, under specific conditions, and must be handled by a specialist in molecular biology. Now, a team of researchers from Pompeu Fabra University has developed new technology to ‘print’ cellular devices on paper that can be used outside the laboratory.

Read more | >

Research papers come out far too rapidly for anyone to read them all, especially in the field of machine learning, which now affects (and produces papers in) practically every industry and company. This column aims to collect some of the most relevant recent discoveries and papers — particularly in but not limited to artificial intelligence — and explain why they matter.

This week brings a few unusual applications of or developments in machine learning, as well as a particularly unusual rejection of the method for pandemic-related analysis.

One hardly expects to find machine learning in the domain of government regulation, if only because one assumes federal regulators are hopelessly behind the times when it comes to this sort of thing. So it may surprise you that the U.S. Environmental Protection Agency has partnered with researchers at Stanford to algorithmically root out violators of environmental rules.

Read more | >

The regeneration of damaged central nervous system (CNS) tissues is one of the biggest goals of regenerative medicine.

Most stroke victims don’t receive treatment fast enough to prevent brain damage. Scientists at The Ohio State University Wexner Medical Center, College of Engineering and College of Medicine have developed technology to “retrain” cells to help repair damaged brain tissue. It’s an advancement that may someday help patients regain speech, cognition and motor function, even when administered days after an ischemic stroke.

Engineering and medical researchers use a process created by Ohio State called tissue nanotransfection (TNT) to introduce genetic material into cells. This allows them to reprogram skin cells to become something different—in this case vascular cells—to help fix damaged tissue.

Study findings published online today in the journal Science Advances.

Read more | >

The future of aviation, planes of the future.

As the aviation industry attempts to recover from the devastating effects of the pandemic, we take a in depth look at the future of flying. Will we soon be boarding commercial jets made in China? Or flying faster than the speed of sound? And what will the planes actually look like? Answers to these questions and more as Rob Watts reports on the future of flight.

Subscribe: https://www.youtube.com/user/deutschewelleenglish?sub_confirmation=1

For more news go to: http://www.dw.com/en/
Follow DW on social media:
►Facebook: https://www.facebook.com/deutschewellenews/
►Twitter: https://twitter.com/dwnews.
►Instagram: https://www.instagram.com/dwnews.
Für Videos in deutscher Sprache besuchen Sie: https://www.youtube.com/dwdeutsch.
#Planes #Aviation #Aircraft

Read more | >

Today at 1 PM PST.

On Sunday, February 212021, at 1 p.m. U.S. Pacific Time, the U.S. Transhumanist Party invites Dr. Aubrey de Grey of the SENS Research Foundation, for an in-depth conversation about recent developments in the quest to reverse the damage of biological aging. The discussion will cover current in rejuvenation research and advocacy, as well as delve into how the prospects for reaching longevity escape velocity have changed since Dr. de Grey’s remarks at the U.S. Transhumanist Party Discussion Panel on Life Extension nearly 4 years ago in 2017.

Dr. Aubrey de Grey is the biomedical gerontologist who researched the idea for and founded SENS Research Foundation — http://www.sens.org/. He received his BA in Computer Science and Ph.D. in Biology from the University of Cambridge in 1985 and 2000, respectively. Dr. de Grey is Editor-in-Chief of Rejuvenation Research, is a Fellow of both the Gerontological Society of America and the American Aging Association, and sits on the editorial and scientific advisory boards of numerous journals and organizations.

Watch this Virtual Enlightenment Salon on YouTube here: https://www.youtube.com/watch?v=ohet4kAfskM

Read more | >